Treatment
Cell clinical trials
We’re tracking 5,686 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT04691817RecruitingPhase 1/Phase 2
Testing tocilizumab plus atezolizumab after lung cancer treatment failure
This trial studies whether combining tocilizumab with atezolizumab can help people with advanced lung cancer that has already stopped responding to an immune checkpoint medicine. It may help when standard immune therapy (and other treatments) aren’t working anymore.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04693377Recruiting
Freezing tumor treatment plus targeted radiation for painful bone spread
This study tests whether combining a “freezing” procedure (cryoablation) with focused external radiation (SBRT) can reduce pain from bone metastases. It’s for people with certain cancers that have spread to bone and are having significant pain in a specific bone spot.
Houston, TexasAges 18 years+ - NCT04720560Recruiting
Study how immune cells affect fatty liver disease
This study looks at how certain immune cells (“regulatory B cells”) may contribute to metabolic fatty liver disease. You might be able to join if you’re an adult with fatty liver but not pregnant and not on certain treatments.
AsyutAges 18–80 - NCT04723095Recruiting
Cervical neuroendocrine cancer registry for past and present patients
This study builds a registry (a secure database) of people who have had cervical neuroendocrine cancer, including small cell or large cell types. It helps researchers learn more about these cancers and may improve future care and research planning.
Houston, TexasAges Any age - NCT04728724RecruitingPhase 2
Check immune treatment before surgery for stage III lung cancer
This Phase 2 trial tests an “immunotherapy” medicine given before surgery for stage III non-small cell lung cancer. The goal is to shrink the cancer and make curative surgery more successful while monitoring safety and response.
ShanghaiAges 18–75 - NCT04729543RecruitingPhase 1/Phase 2
TCR cell therapy for melanoma and head and neck cancer
This early-phase study tests a lab-made T-cell treatment that targets a specific tumor marker (MC2) in melanoma and head and neck cancers. It aims to see if the treatment can safely shrink tumors and control cancer after standard options have run out.
RotterdamAges 18 years+ - NCT04744116RecruitingEarly Phase 1
Cord blood cell therapy added to ruxolitinib for steroid-resistant GVHD
This trial studies whether adding cord-blood–derived cells to ruxolitinib can improve steroid-resistant acute graft-versus-host disease (GVHD) affecting the lower gut or liver. It’s meant for people who are not getting better (or are worsening) despite adequate steroid treatment.
Houston, TexasAges 12–80 - NCT04745403RecruitingPhase 1
Trial of redirected HBV-targeting T cells for liver cancer
This Phase 1 study tests a lab-made immune cell treatment that targets hepatitis B (HBV)–related liver cancer. It may help by directing the body’s immune system to attack the cancer, while carefully checking safety.
SingaporeAges 21–75 - NCT04777175Recruiting
Looking at immunotherapy for lung cancer with rare gene mutations
This study looks back at patients with advanced non-small cell lung cancer who have specific rare gene changes (mutations). It aims to see how well immunotherapy works for people with these exact mutations.
Changsha, HunanAges 18–75 - NCT04784052RecruitingPhase 1/Phase 2
Briquilimab with reduced donor stem cell transplant for Fanconi anemia
This study tests whether a reduced-intensity donor stem cell transplant (with briquilimab as part of the conditioning) can safely treat bone marrow failure in people with Fanconi anemia. It may help by lowering how much intensive treatment is needed before the transplant, while still helping the donor cells grow.
Stanford, CaliforniaAges 2 years+ - NCT04795882RecruitingPhase 1
Study of modular CAR T therapy for multiple myeloma
This early-phase study tests a personalized type of immune therapy called modular CAR T for people with relapsed or treatment-resistant multiple myeloma. It aims to see whether the therapy can reduce the myeloma, including in cases where standard treatments have not worked.
London, County (Optional)Ages 18 years+ - NCT04806412Recruiting
Gene testing in lung cancer fluid samples
This study looks at fluid from around the lungs (pleural fluid) to find gene changes (oncodrivers) in people with non-small cell lung cancer. The goal is to see if this fluid can replace a tissue biopsy for testing.
Næstved, Region SjællandAges 18 years+ - NCT04812431RecruitingPhase 1/Phase 2
Tested stem cell transplant therapy for severe spinal cord injury
This trial tests a cell transplant approach for people with a very severe spinal cord injury. It focuses first on safety and also looks for early signs the therapy may improve function.
Suwon, GyeonggidoAges 18–65 - NCT04838171Recruiting
Study of White Blood Cells in Donors and Patients
This study looks at white blood cells (the body’s immune cells) to learn more about how they behave in health and/or illness. Participation may help researchers understand immune-related changes and support future treatments.
LondonAges Any age - NCT04852328RecruitingPhase 2
Testing CUE-101 schedules before treatment for HPV16 throat cancer
This Phase 2 trial studies different timing “schedules” of CUE-101 given before surgery or before chemoradiation for HPV16-positive oropharyngeal throat cancer. The goal is to see if CUE-101 can help the body respond better and potentially improve outcomes.
St Louis, MissouriAges 18 years+ - NCT04858256RecruitingPhase 2
Pacritinib for relapsed or resistant T-cell blood cancers
This Phase 2 trial studies pacritinib, an oral medicine, for T-cell lymphoma/leukemia that has come back or did not respond to prior treatment. It aims to see how well pacritinib can control the cancer and improve outcomes.
Duarte, CaliforniaAges 18 years+ - NCT04864054RecruitingPhase 1/Phase 2
Study T-cell therapy for advanced liver cancer
This trial tests a custom immune-cell treatment made to target a marker (GPC3) found on some liver cancers. It’s for adults with advanced HCC whose cancer has worsened after standard treatment or who couldn’t tolerate it.
Duarte, CaliforniaAges 18 years+ - NCT04868162RecruitingPhase 2
MRG003 for head and neck cancer after prior treatments
This trial tests MRG003, a cancer medicine, in people with recurrent or metastatic squamous cell carcinoma of the head and neck who have already tried and had trouble with standard treatments like platinum and anti–PD-1 therapy. It looks at whether the treatment can shrink the cancer and how safe it is.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04889716RecruitingPhase 2
CAR-T followed by antibody treatment for lymphoma
This Phase 2 study looks at giving CAR-T cell therapy first, then follow-up “bispecific” antibody medicines to help keep large B-cell lymphoma from coming back. It’s for people whose lymphoma returned or did not respond to prior standard treatments and who still have measurable disease on scans.
Omaha, NebraskaAges 18 years+ - NCT04901702RecruitingPhase 1/Phase 2
Onivyde plus talazoparib or temozolomide for resistant solid tumors
This trial tests whether adding Onivyde to either talazoparib or temozolomide can shrink or control hard-to-treat (refractory or recurring) cancers in children and young adults. It aims to find safer dosing first, then look at how well the treatment works—especially for Ewing sarcoma.
Palo Alto, CaliforniaAges 1–30 - NCT04902937Recruiting
Testing how added radiation may work by immune and tumor markers
This study looks at people with non-metastatic invasive breast cancer who are getting curative breast surgery followed by planned radiation (sometimes with other anti-cancer medicines). Researchers want to understand whether a patient’s age and certain immune/tumor blood features can predict how well radiation helps.
JenaAges 18 years+ - NCT04912765RecruitingPhase 2
New immune vaccine plus nivolumab for liver cancer
This trial studies whether an individualized “neoantigen” cancer vaccine given to immune cells (dendritic cells) plus nivolumab can improve outcomes in people with liver cancer and/or colorectal cancer that has spread only to the liver. It focuses on tumors that can be removed with curative surgery (with or without local ablation) and on people with good enough liver and overall health.
SingaporeAges 21 years+ - NCT04913311Recruiting
Testing markers to predict lung inflammation after lung cancer treatment
This study looks for early “predictive markers” to tell who is most likely to develop lung inflammation after standard treatment for non-small cell lung cancer. It may help clinicians spot problems sooner and tailor care, using additional monitoring during treatment.
Houston, TexasAges Any age - NCT04922567RecruitingPhase 2
Lenalidomide plus CHOP versus CHOP for untreated PTCL
This Phase 2 trial compares two chemotherapy approaches—adding lenalidomide to CHOP versus CHOP alone—for people with untreated peripheral T-cell lymphoma (PTCL). The goal is to see if the added medicine improves response and safety.
Hangzhou, ZhejiangAges 18–75
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,686 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.